Please login to the form below

Not currently logged in
Email:
Password:

Michael Wyzga OncoMed board

He brings financial experience from Genzyme

Michael Wyzga OncoMedOncoMed has appointed industry veteran Michael Wyzga to the company's board of directors.

The cancer specialist is looking to make the most of Wyzga's years in the industry as it prepares to advance the development of its five drug candidates, with several new filings planned for 2014.

This experience includes serving as chief financial officer of the biotech Genzyme from 1998 to 2011, when the company was acquired by Sanofi in what was the second-largest acquisition in biotech history.

He is currently president and CEO of biopharma company Radius Health having joined the company in December 2011.

"As a CEO of an emerging biopharmaceuticals company and previous chief financial officer of one of the leading biotechnology companies in the world, Mike brings an excellent perspective to OncoMed's board following our successful initial public offering," said Paul Hastings, chairman and CEO of OncoMed.

In addition to its own prospects, OncoMed also has development deals with major pharma companies, including GlaxoSmithKline and Bayer.

23rd October 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics